| Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of … S Slavin, A Nagler, E Naparstek, Y Kapelushnik, M Aker, G Cividalli, ... Blood, The Journal of the American Society of Hematology 91 (3), 756-763, 1998 | 2671 | 1998 |
| Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma RL Piekarz, R Frye, M Turner, JJ Wright, SL Allen, MH Kirschbaum, J Zain, ... Journal of clinical oncology 27 (32), 5410-5417, 2009 | 862 | 2009 |
| Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma RL Piekarz, R Frye, HM Prince, MH Kirschbaum, J Zain, SL Allen, ES Jaffe, ... Blood, The Journal of the American Society of Hematology 117 (22), 5827-5834, 2011 | 543 | 2011 |
| Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia M Andreeff, KR Kelly, K Yee, S Assouline, R Strair, L Popplewell, ... Clinical Cancer Research 22 (4), 868-876, 2016 | 367 | 2016 |
| Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study A Younes, A Sureda, D Ben-Yehuda, PL Zinzani, TC Ong, HM Prince, ... Journal of Clinical Oncology 30 (18), 2197-2203, 2012 | 320 | 2012 |
| A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in … A Nademanee, S Forman, A Molina, H Fung, D Smith, A Dagis, C Kwok, ... Blood 106 (8), 2896-2902, 2005 | 250 | 2005 |
| Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma M Kirschbaum, P Frankel, L Popplewell, J Zain, M Delioukina, V Pullarkat, ... Journal of clinical oncology 29 (9), 1198-1203, 2011 | 231 | 2011 |
| The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph− acute lymphoblastic leukemia cells A Scuto, M Kirschbaum, C Kowolik, L Kretzner, A Juhasz, P Atadja, ... Blood, The Journal of the American Society of Hematology 111 (10), 5093-5100, 2008 | 170 | 2008 |
| Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome EJ Dann, R Bar-Shalom, A Tamir, N Haim, M Ben-Shachar, I Avivi, ... Blood 109 (3), 905-909, 2007 | 159 | 2007 |
| A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome M Kirschbaum, I Gojo, SL Goldberg, C Bredeson, LA Kujawski, A Yang, ... British journal of haematology 167 (2), 185-193, 2014 | 139 | 2014 |
| Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial N Jain, E Curran, NM Iyengar, E Diaz-Flores, R Kunnavakkam, ... Clinical cancer research 20 (2), 490-498, 2014 | 139 | 2014 |
| HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen N Li, D Zhao, M Kirschbaum, C Zhang, CL Lin, I Todorov, F Kandeel, ... Proceedings of the National Academy of Sciences 105 (12), 4796-4801, 2008 | 119 | 2008 |
| Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels L Kretzner, A Scuto, PM Dino, CM Kowolik, J Wu, P Ventura, R Jove, ... Cancer research 71 (11), 3912-3920, 2011 | 112 | 2011 |
| Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas F Yang, TE Van Meter, R Buettner, M Hedvat, W Liang, CM Kowolik, ... Molecular cancer therapeutics 7 (11), 3519-3526, 2008 | 104 | 2008 |
| Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease F Lopez, P Parker, A Nademanee, R Rodriguez, Z Al-Kadhimi, R Bhatia, ... Biology of Blood and Marrow Transplantation 11 (4), 307-313, 2005 | 98 | 2005 |
| Chronic graft-versus-host disease treated with UVB phototherapy CD Enk, S Elad, A Vexler, J Kapelushnik, R Gorodetsky, M Kirschbaum Bone marrow transplantation 22 (12), 1179-1183, 1998 | 93 | 1998 |
| A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517 MH Kirschbaum, BH Goldman, JM Zain, JR Cook, LM Rimsza, SJ Forman, ... Leukemia & lymphoma 53 (2), 259-262, 2012 | 87 | 2012 |
| A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma R Chen, P Frankel, L Popplewell, T Siddiqi, N Ruel, A Rotter, SH Thomas, ... Haematologica 100 (3), 357, 2015 | 84 | 2015 |
| A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia … MH Kirschbaum, KA Foon, P Frankel, C Ruel, B Pulone, JM Tuscano, ... Leukemia & lymphoma 55 (10), 2301-2304, 2014 | 82 | 2014 |
| SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells A Scuto, M Kirschbaum, R Buettner, M Kujawski, JM Cermak, P Atadja, ... Cell death & disease 4 (5), e635-e635, 2013 | 75 | 2013 |
